| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net revenues | 42 | 78 | 46 | 56 |
| Cost of goods sold | 203 | 234 | 226 | 187 |
| Research and development | 2,700 | 2,485 | 2,748 | 2,757 |
| Sales and marketing | 405 | 361 | 358 | 394 |
| General and administrative | 2,442 | 2,068 | 1,821 | 1,692 |
| Total costs and operating expenses | 5,750 | 5,148 | 5,153 | 5,030 |
| Change in fair value of forward purchase agreement put option liability | - | 0 | - | - |
| Operating loss | -5,708 | -5,070 | -5,107 | -4,974 |
| Change in fair value of forward purchase agreement warrant liability | -64 | -37 | -421 | 311 |
| Interest expense, other | - | - | - | 264 |
| Change in fair value of private warrant liability | 339 | - | - | - |
| Change in fair value of publicly traded warrant liability | 33 | 32 | -194 | 426 |
| Interest expense, related party | 471 | 624 | 495 | - |
| Other income (expense), net | 5 | -1 | -11 | 15 |
| Total other income (expense), net | -774 | -620 | 109 | -986 |
| Net loss | -6,482 | -5,690 | -4,998 | -5,960 |
| Cumulative preferred dividends and undistributed earnings allocated to participating securities b | - | - | - | 1,380 |
| Cumulative preferred dividends | 1,265 | 1,252 | 1,238 | - |
| Net loss attributable to common stockholders, basic | -7,747 | -6,942 | -6,236 | -7,340 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.35 | -0.32 | -0.29 | -0.37 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.35 | -0.32 | -0.29 | -0.37 |
| Weighted-average class a common stock outstanding, basic (in shares) | 21,851,606 | 21,383,852 | 21,326,609 | 19,616,362 |
| Weighted-average class a common stock outstanding, diluted (in shares) | 21,851,606 | 21,383,852 | 21,326,609 | 19,616,362 |
Envoy Medical, Inc. (COCH)
Envoy Medical, Inc. (COCH)